Fgf9 signaling regulates small intestinal elongation and mesenchymal development
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Short bowel syndrome is an acquired condition in which the length of the small intestine is insufficient to perform its normal absorptive function. Current therapies are limited as the developmental mechanisms that normally regulate elongation of the small intestine are poorly understood. Here, we identify Fgf9 as an important epithelial-to-mesenchymal signal required for proper small intestinal morphogenesis. Mouse embryos that lack either Fgf9 or the mesenchymal receptors for Fgf9 contained a disproportionately shortened small intestine, decreased mesenchymal proliferation, premature differentiation of fibroblasts into myofibroblasts and significantly elevated Tgfβ signaling. These findings suggest that Fgf9 normally functions to repress Tgfβ signaling in these cells. In vivo, a small subset of mesenchymal cells expressed phospho-Erk and the secreted Tgfβ inhibitors Fst and Fstl1 in an Fgf9-dependent fashion. The p-Erk/Fst/Fstl1-expressing cells were most consistent with intestinal mesenchymal stem cells (iMSCs). We found that isolated iMSCs expressed p-Erk, Fst and Fstl1, and could repress the differentiation of intestinal myofibroblasts in co-culture. These data suggest a model in which epithelial-derived Fgf9 stimulates iMSCs that in turn regulate underlying mesenchymal fibroblast proliferation and differentiation at least in part through inhibition of Tgfβ signaling in the mesenchyme. Taken together, the interaction of FGF and TGFβ signaling pathways in the intestinal mesenchyme could represent novel targets for future short bowel syndrome therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 2×
“For example, it has been recently shown that MSCs have the potential to play a role in disease by functioning as a nidus of paracrine signaling (Gnecchi et al., 2006; Karnoub et al., 2007).”
Background
Cited by
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Self-citationElmentaite, R., Ross, A. D. B., Roberts, K., James, K. R., Ortmann, D., Gomes, T., Nayak, K., Tuck, L., Pritchard, S., Bayraktar, O. A., et al. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.11.010 · Cited by 316
Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota
Nagashima, K., Sawa, S., Nitta, T., Tsutsumi, M., Okamura, T., Penninger, J. M., Nakashima, T., & Takayanagi, H. (2017) · Nature Immunology · doi:10.1038/ni.3732 · Cited by 154
Mesothelium and Malignant Mesothelioma
Hiriart, E., Deepe, R., & Wessels, A. (2019) · Journal of Developmental Biology · doi:10.3390/jdb7020007 · Cited by 66
“It is, however, not completely clear whether this is mainly the result of the absence of FGF9 from the endoderm or whether the absence of FGF9 from the mesothelial cells plays a role in the pathogenesis as well [71].”
BackgroundLoss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon
Hamilton, K. E., Chatterji, P., Lundsmith, E. T., Andres, S. F., Giroux, V., Hicks, P. D., Noubissi, F. K., Spiegelman, V. S., & Rustgi, A. K. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0224 · Cited by 52
Metadata
- Authors
- Geske, M. J., Zhang, X., Patel, K. K., Ornitz, D. M., & Stappenbeck, T. S.
- Venue
- Development
- Publisher
- The Company of Biologists
- Published
- 2008-09-01
- Volume
- 135
- Issue
- 17
- Pages
- 2959-2968
- ISSN
- 0950-1991 (ISSN-L)
- 1477-9129
- OpenAlex
- W2017109082
- Cited by
- 85
- References
- 1
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.